Patient-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Omicron Variants and Confers Full Protection in Monkeys

To provide additional therapies against Omicron, researchers isolated a monoclonal antibodies named P2G3 from a previously infected vaccinated donor and showed that it has picomolar-range neutralizing activity against Omicron BA.1, BA.1.1, BA.2, and all other variants tested.